Sanofi India has delivered a strong financial performance for the second quarter of 2026, powered by double-digit growth in its diabetes portfolio, expanding public sector business and improved operational efficiency.

 

The company reported 8% growth in domestic net sales and 6% growth in total net sales for the quarter ended June 30, 2026, compared with the second quarter of 2025.

 

Sanofi India’s insulin portfolio maintained its strong momentum, registering 14% double-digit growth for the second consecutive quarter. The performance strengthened the company’s leadership in the basal analog insulin market, with a 58% value market share and 61% volume market share. Growth was driven by key brands including Lantus, Toujeo, and Apidra, along with the continued success of Soliqua, the company’s premium offering in the premix diabetes segment.

 

The company’s public sector business recorded a sharp 70% growth, supported by the addition of new accounts for Toujeo and Soliqua through the CARE Accounts initiative. The move further expanded Sanofi’s presence in India’s diabetes injectable market.

 

Sanofi India also reported progress across its strategic partnerships in Cardiovascular, Oral anti-Diabetes and Central Nervous System segments, helping expand market reach. Partnership revenues grew 2% in Q2 2026, supported by continued returns from the company’s expanded commercial footprint.

 

Export sales remained stable, reflecting the resilience of Sanofi India’s international operations despite global challenges.

 

Profit before tax and exceptional items rose 19% to Rs. 112 crore in Q2 2026, compared with Rs. 94 crore in the same quarter last year. Profit before tax margin improved to 27% of net sales, up from 24% in Q2 2025.

 

The improvement was driven by a favourable product mix and disciplined cost management, with operating expenses — including employee costs and other expenses — declining 5% compared with the second quarter of 2025.

 

Deepak Arora, Managing Director, Sanofi India, said: "Q2 2026 marks another chapter of purposeful, profitable growth for Sanofi India, with our diabetes portfolio posting double-digit growth for the second consecutive quarter and profit before tax growing 19%. These results reflect the discipline and momentum we have built across the business.

 

"Our acceleration in the public sector demonstrates that we are not just growing; we are broadening access to innovative therapies across the country. With a 57.3% value share in the diabetes injectable segment, a modernized go-to-market model, and a business that has grown 17% in the first half of 2026, the foundation for sustainable, long-term value creation is firmly in place.

 

"As we mark seven decades of serving Indian patients, guided by our purpose to chase the miracles of science, we remain focused on capturing the immense growth opportunity that India's diabetes landscape presents."